Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: High local control with low toxicity

Neuro-Oncology

Volumn 13, Issue 8, 2011, Pages 916-922

  Iwata, Hiromitsu ^a,b   Sato, Kengo ^b   Tatewaki, Koshi ^b   Yokota, Naoki ^b   Inoue, Mitsuhiro ^c   Baba, Yoshimi ^e   Shibamoto, Yuta ^d  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Department of Neurosurgery ^*  (Japan)

^c Division of Quality Management with Radiation   (Japan)

^d Yokohama CyberKnife Center   (Japan)

^e OKAYAMA KYOKUTO HOSPITAL   (Japan)

Author keywords

CyberKnife; Hypofractionated stereotactic radiotherapy; Nonfunctioning; Optic pathway; Pituitary adenoma.

Indexed keywords

ABDUCENS NERVE PARALYSIS; ADULT; AGED; ARTICLE; BRAIN NECROSIS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CYBERKNIFE; FEMALE; FOLLOW UP; HUMAN; HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; MAJOR CLINICAL STUDY; MALE; OPHTHALMOPLEGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE; TREATMENT OUTCOME; VISUAL DISORDER;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES; RADIOSURGERY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052732374     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor055     Document Type: Article

References (33)

1. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101: 613-619. (Pubitemid 38970613)
2. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol. 2006;8:27-37. (Pubitemid 43154448)
3. Losa M, Mortini P, Barzaghi R, et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg. 2008;108:525-532. (Pubitemid 351357985)
4. Brochier S, Galland F, Kujas M, et al. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol. 2010;163:193-200.
5. Park P, Chandler WF, Barkan AL, et al. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery. 2004;55:100-106. (Pubitemid 38859084)
6. Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol. 1993;38:571-578. (Pubitemid 23168470)
7. Sasaki R, Murakami M, Okamoto Y, et al. The efficacy of conventional radiation therapy in the management of pituitary adenoma. Int J Radiat Oncol Biol Phys. 2000;47:1337-1345. (Pubitemid 30421187)
8. Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol. 2009;93:597-601.
9. Kobayashi T. Long-term results of stereotactic gamma knife radiosurgery for pituitary adenomas. Specific strategies for different types of adenoma. Prog Neurol Surg. 2009;22:77-95.
10. Mingione V, Yen CP, Vance ML, et al. Gamma surgery in the treatment of nonsecretory pituitary macroadenoma. J Neurosurg. 2006;104:876-883. (Pubitemid 43824736)
11. Pollock BE, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys. 2008;70:1325-1329. (Pubitemid 351417753)
12. Tishler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys. 1993;27:215-221. (Pubitemid 23304445)
13. Leber KA, Berglö ff J, Pendl G. Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. J Neurosurg. 1998;88:43-50. (Pubitemid 28018962)
14. Stafford SL, Pollock BE, Leavitt JA, et al. A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2003;55:1177-1181. (Pubitemid 36338281)
15. Shigematsu N, Kunieda E, Kawaguchi O, et al. Indications of stereotactic irradiation for brain lesions. Acta Oncol. 2000;39:597-603.
16. Hoban PW, Jones LC, Clark BG. Modeling late effects in hypofrationated stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43:199-210. (Pubitemid 29065845)
17. Snead FE, Amdur RJ, Morris CG, et al. Long-term outcomes of radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys. 2008;71:994-998.
18. Minniti G, Traish D, Ashley S, et al. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas. Clin Endocrinol. 2006;64:542-548.
19. Ronson BB, Schulte RW, Han KP, Loredo LN, Slater JM, Slater JD. Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys. 2006;64:425-434. (Pubitemid 43083429)
20. Inoue H, Omori R, Sato K, et al. The accuracy of the CyberKnife. J Jpn Soc Ther Radiol Oncol. 2003;15:177-185. (Pubitemid 37295672)
21. Chang SD, Main W, Martin DP, Gibbs IC, Heilbrun MP. An analysis of the accuracy of the CyberKnife: a robotic frameless stereotactic radiosurgical system. Neurosurgery. 2003;52:140-146; discussion 146-147.
22. Antypas C, Pantelis E. Performance evaluation of a CyberKnife G4 image-guided robotic stereotactic radiosurgery system. Phys Med Biol. 2008;53:4697-4718.
23. Shaw E, Kline R, Gillin M, et al. Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys. 1993;27:1231-1239. (Pubitemid 23361609)
24. Iwata H, Shibamoto Y, Murata R, et al. Estimation of errors associated with use of linear-quadratic formalism for evaluation of biologic equivalence between single and hypofractionated radiation doses: an in vitro study. Int J Radiat Oncol Biol Phys. 2009;75:482-488.
25. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:847-852. (Pubitemid 351199730)
26. Shibamoto Y, Kitakabu Y, Murata R, et al. Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation. Int J Radiat Oncol Biol Phys. 1994;29:583-586. (Pubitemid 24187933)
27. Tomita N, Shibamoto Y, Ito M, et al. Biological effect of intermittent radiation exposure in vivo: recovery from sublethal damage versus reoxygenation. Radiother Oncol. 2008;86:369-374. (Pubitemid 351335442)
28. Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys. 2010;76(suppl):28-35.
29. Adler JR, Jr, Gibbs IC, Puataweepong P, et al. Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions. Neurosurgery. 2008;62(suppl):733-743.
30. Pinker K, Ba-Ssalamah A, Wolfsberger S, Mlynarik V, Knosp E, Trattnig S. The value of high-field MRI (3T) in the assessment of sellar lesions. Eur J Radiol. 2005;54:327-334. (Pubitemid 40719722)
31. Satogami N, Miki Y, Koyama T, Kataoka M, Togashi K. Normal pituitary stalk: high-resolution MR imaging at 3T. AJNR Am J Neuroradiol. 2010;31:355-359.
32. Chernov MF, Kawamata T, Amano K, et al. Possible role of single-voxel (1)H-MRS in differential diagnosis of suprasellar tumors. J Neurooncol. 2009;91:191-198.
33. Masutani Y, Aoki S, Abe O, Hayashi N, Otomo K. MR diffusion tensor imaging: recent advance and new techniques for diffusion tensor visualization. Eur J Radiol. 2003;46:53-66. (Pubitemid 36332079)